Mostra el registre parcial de l'element

dc.contributor.authorDietl, Beatriz
dc.contributor.authorBoix Palop, Lucía
dc.contributor.authorGisbert, Laura
dc.contributor.authorMateu, Aina
dc.contributor.authorGarreta, Gemma
dc.contributor.authorXercavins, Mariona
dc.contributor.authorBadía, Cristina
dc.contributor.authorLópez Sánchez, María
dc.contributor.authorPérez, Josefa
dc.contributor.authorCalbo, Esther
dc.date.accessioned2023-05-02T13:57:18Z
dc.date.available2023-05-02T13:57:18Z
dc.date.issued2023
dc.identifier.citationDietl, Beatriz; Boix Palop, Lucía; Gisbert, Laura [et al.]. Risk factors associated with inappropriate empirical antimicrobial treatment in bloodstream infections. A cohort study. Frontiers in Pharmacology, 2023, 14, 1132530. Disponible en: <https://www.frontiersin.org/articles/10.3389/fphar.2023.1132530/full>. Fecha de acceso: 2 may. 2023. DOI: 10.3389/fphar.2023.1132530ca
dc.identifier.issn1663-9812ca
dc.identifier.urihttp://hdl.handle.net/20.500.12328/3686
dc.description.abstractIntroduction: Bloodstream infections (BSI) are a major cause of mortality all over the world. Inappropriate empirical antimicrobial treatment (i-EAT) impact on mortality has been largely reported. However, information on related factors for the election of i-EAT in the treatment of BSI in adults is lacking. The aim of the study was the identification of risk-factors associated with the use of i-EAT in BSI. Methods: A retrospective, observational cohort study, from a prospective database was conducted in a 400-bed acute-care teaching hospital including all BSI episodes in adult patients between January and December 2018. The main outcome variable was EAT appropriation. Multivariate analysis using logistic regression was performed. Results: 599 BSI episodes were included, 146 (24%) received i-EAT. Male gender, nosocomial and healthcare-associated acquisition of infection, a high Charlson Comorbidity Index (CCI) score and the isolation of multidrug resistant (MDR) microorganisms were more frequent in the i-EAT group. Adequation to local guidelines’ recommendations on EAT resulted in 91% of appropriate empirical antimicrobial treatment (a-EAT). Patients receiving i-EAT presented higher mortality rates at day 14 and 30 when compared to patients with a-EAT (14% vs. 6%, p = 0.002 and 22% vs. 9%, p < 0.001 respectively). In the multivariate analysis, a CCI score ≥3 (OR 1.90 (95% CI 1.16–3.12) p = 0.01) and the isolation of a multidrug resistant (MDR) microorganism (OR 3.79 (95% CI 2.28–6.30), p < 0.001) were found as independent risk factors for i-EAT. In contrast, female gender (OR 0.59 (95% CI 0.35–0.98), p = 0.04), a correct identification of clinical syndrome prior to antibiotics administration (OR 0.26 (95% CI 0.16–0.44), p < 0.001) and adherence to local guidelines (OR 0.22 (95% CI 0.13–0.38), p < 0.001) were identified as protective factors against i-EAT. Conclusion: One quarter of BSI episodes received i-EAT. Some of the i-EAT related factors were unmodifiable (male gender, CCI score ≥3 and isolation of a MDR microorganism) but others (incorrect identification of clinical syndrome before starting EAT or the use of local guidelines for EAT) could be addressed to optimize the use of antimicrobials.en
dc.format.extent10ca
dc.language.isoengca
dc.publisherFrontiers Mediaca
dc.relation.ispartofFrontiers in Pharmacologyca
dc.relation.ispartofseries14
dc.relation.urihttps://www.frontiersin.org/articles/10.3389/fphar.2023.1132530/fullca
dc.rights© 2023 Dietl, Boix-Palop, Gisbert, Mateu, Garreta, Xercavins, Badía, López-Sánchez, Pérez and Calbo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.ca
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subject.otherBacterièmiaca
dc.subject.otherInfeccions del torrent sanguini (BSI)ca
dc.subject.otherAgents antibacteriansca
dc.subject.otherÚs terapèuticca
dc.subject.otherFactors de riscca
dc.subject.otherTeràpia antimicrobianaca
dc.subject.otherIntervenció de la gestió antimicrobiana (ASP)ca
dc.subject.otherBacteriemiaes
dc.subject.otherInfecciones del torrente sanguíneo (BSI)es
dc.subject.otherUso terapéutico de agentes antibacterianoses
dc.subject.otherFactores de riesgoes
dc.subject.otherTerapia antimicrobianaes
dc.subject.otherIntervención de administración antimicrobiana (ASP)es
dc.subject.otherBacteremiaen
dc.subject.otherBloodstream infections (BSI)en
dc.subject.otherAnti-bacterial agents-therapeutic useen
dc.subject.otherRisk factorsen
dc.subject.otherAntimicrobial therapyen
dc.subject.otherAntimicrobial stewardship (ASP) interventionen
dc.titleRisk factors associated with inappropriate empirical antimicrobial treatment in bloodstream infections. A cohort studyen
dc.typeinfo:eu-repo/semantics/articleca
dc.description.versioninfo:eu-repo/semantics/publishedVersionca
dc.rights.accessLevelinfo:eu-repo/semantics/openAccess
dc.embargo.termscapca
dc.subject.udc61ca
dc.identifier.doihttps://dx.doi.org/10.3389/fphar.2023.1132530ca


Fitxers en aquest element

 

Aquest element apareix en la col·lecció o col·leccions següent(s)

Mostra el registre parcial de l'element

© 2023 Dietl, Boix-Palop, Gisbert, Mateu, Garreta, Xercavins, Badía, López-Sánchez, Pérez and Calbo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Excepte que s'indiqui una altra cosa, la llicència de l'ítem es descriu com https://creativecommons.org/licenses/by/4.0/
Comparteix a TwitterComparteix a LinkedinComparteix a FacebookComparteix a TelegramComparteix a WhatsappImprimeix